C. Chauvin

Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma

P. Moreau, C. Touzeau, B. Mahé, 2014, Haematologica.

Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients.

P. Chevallier, M. Mohty, M. Béné, 2016, Seminars in hematology.

Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study

P. Chevallier, P. Moreau, M. Péré, 2017, Antimicrobial Agents and Chemotherapy.

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases

P. Chevallier, P. Moreau, C. Touzeau, 2018, Leukemia research reports.

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.

P. Moreau, C. Touzeau, B. Mahé, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.